Bristol-Myers Squibb (NYSE: BMY) reported Q4 EPS of $0.63, $0.04 worse than the analyst estimate of $0.67. Revenue for the quarter came in at $5.24 billion versus the consensus estimate of $5.13 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2017 EPS of $2.70-$2.90, versus the consensus of $2.96.

"Bristol-Myers Squibb achieved outstanding operating and financial results in 2016, driven by strong commercial performance across our portfolio,” said Giovanni Caforio, M.D., chief executive officer, Bristol-Myers Squibb. “In 2017, we will continue to advance our pipeline, drive strong commercial execution across the business and progress our broad portfolio of Immuno-Oncology medicines.”

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.